4 news items
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
23 May 24
to be delivered directly to the lymph nodes, with the goal of enhancing the immune system's cancer-fighting capabilities. By targeting cancer immunotherapies
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
ELTX
15 May 24
technology, which allows for therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system's cancer
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
25 Apr 24
to the lymph nodes, with the goal of enhancing the immune system's cancer-fighting capabilities. By targeting cancer immunotherapies to the core of the immune
Elicio Therapeutics Celebrates 13 Years Developing Innovative Cancer Immunotherapies
ELTX
24 Apr 24
goal is to produce vaccines, immunomodulators, and adjuvants that help patients produce the best cells for fighting various cancers, and potentially
- Prev
- 1
- Next